Consistently, by conducting the trypan blue staining assay, we found that the inhibitors for AMPK-ULK1 pathway also aggravated the inhibiting effects of doxorubicin on cell viability in DR-BC cells (Fig. 5c). Here, ULK1 is linked to breast cancer.